B. Braun Melsungen Ag

Sebo Gmbh

Other

Boehringer Mannheim Gmbh

Thermo Finnigan LLC

Novartis International Pharmaceutical, Ltd.

B. Braun Medizintechnologie Gmbh

Safe Bt, Inc.

Vermögensverwaltung D. Th. Seidel Gmbh

Dietrich Seidel

Karl-Siegfried Boos

Gudrun Henke

Andreas Rauh

Klaus Spengler

Gerold Morsch

Annette Trautwein

Wolf-Dieter Engel

Angelika Kurrle-Weittenhiller

Beate Roxane Jaeger

The present invention relates to an agent comprising anion-exchange groups that are suitable for adsorbing bacterial lipopolysaccharides (LPS) and/or lipoteichoic acids (LTA), for use in the prevention and/or treatment of inflammatory conditions and/or diseases of the oral cavity or in the vaginal region. The present invention also relates to a pharmaceutical composition that comprises an agent of this kind and can adhere to mucosa.

Agent for use for inflammatory conditions of mucous membranes

The present invention refers to a method of processing a biological fluid which comprises cellular components by a freezing/thawing treatment. The method is particularly useful for preparing biological samples for analyte detection.

Disintegration of cellular components in whole blood by freeze-thawing

The present invention refers to a method of processing a biological fluid which comprises cellular components by heat treatment. The method is particularly useful for preparing biological samples for analyte detection. Further, the invention refers to a processed biological fluid comprising substantially quantitatively disintegrated cellular components.

Method and device for processing a biological fluid for analyte determination

A device for removing bacterial lipopolysaccharides and lipoteichoic acids from blood or plasma in an extracorporeal perfusion system contains, in a housing that can be incorporated into the perfusion system, a hollow fiber material that is suitable for the selective removal of bacterial lipopolysaccharides and lipoteichoic acids, the device being arranged in such a way that the blood or plasma entering through a first opening of the housing must pass through the hollow fiber material before it leaves through a second opening of the housing and is directed to the rest of the perfusion circuit.

Device for removing bacterial lipopolysaccharides and/or lipoteichoic acids from protein-containing fluids and its use for the treatment of sepsis

The invention relates to the use of an adsorption material which has been modified with polynuclear metal oxide hydroxides for influencing the calcium level and, in particular, for treating or/and preventing atherosclerotic vascular diseases or/and disturbances of bone metabolism.

Use of a phosphate adsorbent to combat vascular diseases

The present invention concerns the use of an adsorbent material modified with polynuclear metal oxyhydroxides for the selective elimination of inorganic phosphate from liquids, in particular from body fluids containing protein such as whole blood, plasma, liquid contents of the intestine as well as from dialysis fluid, as well as a process for the production of a pharmaceutical agent for oral application for the selective removal of inorganic phosphate in which an adsorbent material used according to the present invention, as such or pressed into powder form, is coated with a layer resistant to gastric acid or dispensed into an acid-resistant capsule. In order to selectively eliminate inorganic phosphate in an extracorporeal perfusion system, a body fluid such as whole blood or plasma is passed over one of the adsorbent materials.

Process for the selective elimination of inorganic phosphate from

A process and a reagent for the specific and direct determination of the LDL-fraction in the presence of other serum lipoproteins by adding a polymeric LDL-aggregating agent, followed by direct turbidimetric measurement of the LDL aggregate. Preferred are polymers which have a comb or brush type structure with the side groups having acid character, such as branched alkane sulfonic acids.

Process and reagent for the specific determination of LDL in serum

In order to remove tumor necrosis factor .alpha. (TNF.alpha.) or/and bacterial lipopolysaccharides (LPS, endotoxin) extracorporeally from whole blood or/and blood plasma in an extracorporeal perfusion system, the blood or plasma is passed over a cation exchanger and an anion exchanger material. A device according to the invention for the extracorporeal treatment of patient's blood or plasma therefore contains a cation exchanger material and an anion exchanger material wherein these materials are contained in at least one compartment of an extracorporeal perfusion system.

Process and device for the simultaneous extracorporeal elimination of

Disclosed is a process to remove tumour necrosis factor .alpha. (TNF.alpha.) or/and bacterial lipopolysaccharides (LPS) from an aqueous liquid, in particular blood, blood plasma or serum, in an extracorporeal perfusion system after removing corpuscular blood components if necessary, wherein (a) the pH value of the body fluid is adjusted to pH&lt;6, (b) a precipitation reagent in the form of a polyanion is added, (c) precipitated substances are removed by filtration or/and centrifugation and (d) the resulting liquid is passed over an anion exchanger.

Growing community of inventors

Feldafing, Germany

Dietrich Seidel